Evidence map›Paper›PMID 30291029›Full record

ArticleImmunity2018

Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution.

Jonathan D Proto, Amanda C Doran, Galina Gusarova, Arif Yurdagul, Erdi Sozen, Manikandan Subramanian, Mohammad N Islam, Christina C Rymond, Jasper Du, Jaime Hook and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 293 papers.

0numbers the graph read from it
0cells of the map it votes in
293citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

293 citing papers in PubMed, 425 citations in OpenAlex.

  1. Article
  2. IL-17D reprograms CD93Cellular & molecular immunology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. NLRC5-Deficient Macrophages Promote a Tumor-Permissive Phenotype via AXL- and MERTK-Mediated Efferocytosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  9. Review
  10. Defective efferocytosis in diabetes: molecular mechanisms and emerging therapeutic strategies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  11. Review
  12. CIITA/PRMT5 promote CD4BMC medicine · 2026
    Article
  13. Article
  14. Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026
    Review
  15. Article
  16. Article
  17. CNS1-dependent regulatory T cells shape recovery from acute lung injury.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
  18. Review
  19. Advances in understanding mitophagy's role in lung injury.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026
    Review
  20. Article

233 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Jonathan D ProtoDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Amanda C DoranDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Galina GusarovaDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Arif YurdagulDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Erdi SozenDepartment of Medicine, Columbia University, New York, NY 10032, USA; Department of Biochemistry, Marmara University, Istanbul, Turkey.
Manikandan SubramanianDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Mohammad N IslamDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Christina C RymondDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Jasper DuDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Jaime HookDepartment of Medicine, Columbia University, New York, NY 10032, USA.
George KuriakoseDepartment of Medicine, Columbia University, New York, NY 10032, USA.
Jahar BhattacharyaDepartment of Medicine, Columbia University, New York, NY 10032, USA; Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032, USA.
Ira TabasDepartment of Medicine, Columbia University, New York, NY 10032, USA; Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. Electronic address: iat1@columbia.edu.
Columbia University · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Translational Biomarker Analytical Core (TBAC)P30DK063608 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Anthony W Ferrante · 2003 to 2026
$36.7M
POSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCHT32HL007343 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HENRY N GINSBERG, Muredach P Reilly · 1985 to 2026
$12.7M
MECHANISMS OF BETA CELL FAILURER01DK064819 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ACCILI, DOMENICO · 2003 to 2025
$10.5M
The Unfolded Protein Response in Sterol CytoxicityR01HL075662 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TABAS, IRA A · 2004 to 2017
$5.6M
Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of BiologicsR01HL127464 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHI, JINJUN, TABAS, IRA A · 2016 to 2019
$3.0M
Mitochondrial dynamics in acute lung injuryR01HL122730 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BHATTACHARYA, JAHAR · 2015 to 2018
$1.8M
"MerTK Cleavage and Signaling in Atherosclerosis"R01HL132412 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TABAS, IRA A · 2016 to 2018
$1.5M
NCI NIH HHS P30 CA013696NHLBI NIH HHS R01 HL075662NHLBI NIH HHS R01 HL122730NHLBI NIH HHS R01 HL127464NHLBI NIH HHS R01 HL132412NHLBI NIH HHS T32 HL007343NIDDK NIH HHS P30 DK063608NIDDK NIH HHS R01 DK064819
6 · The paper itself

Abstract

Regulatory T (Treg) cell responses and apoptotic cell clearance (efferocytosis) represent critical arms of the inflammation resolution response. We sought to determine whether these processes might be linked through Treg-cell-mediated enhancement of efferocytosis. In zymosan-induced peritonitis and lipopolysaccharide-induced lung injury, Treg cells increased early in resolution, and Treg cell depletion decreased efferocytosis. In advanced atherosclerosis, where defective efferocytosis drives disease progression, Treg cell expansion improved efferocytosis. Mechanistic studies revealed the following sequence: (1) Treg cells secreted interleukin-13 (IL-13), which stimulated IL-10 production in macrophages; (2) autocrine-paracrine signaling by IL-10 induced Vav1 in macrophages; and (3) Vav1 activated Rac1 to promote apoptotic cell engulfment. In summary, Treg cells promote macrophage efferocytosis during inflammation resolution via a transcellular signaling pathway that enhances apoptotic cell internalization. These findings suggest an expanded role of Treg cells in inflammation resolution and provide a mechanistic basis for Treg-cell-enhancement strategies for non-resolving inflammatory diseases.

Indexed as

AnimalsApoptosisCell LineCells, CulturedHumansInflammationInterleukin-10Interleukin-13Jurkat CellsLipopolysaccharidesLung DiseasesMacrophagesMice, Inbred C57BLMice, KnockoutPeritonitisPhagocytosisInterleukin-10Interleukin-13LipopolysaccharidesZymosanefferocytosisinflammation resolutionmacrophagesregulatory T cells

Identifiers

PMID30291029
PMCPMC6192849
OpenAlexW2894606588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.